Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Korean Journal of MedicineOpen Access

Molecular Residual Disease Monitoring and Early Recurrence Prediction in Solid Tumors: Clinical Applications and Evidence

View Full Paper
Ask AI
Bookmark
Share

Authors

SLSung Hee Lim

Discussion

Loading...

Member takes

Overview

Review highlights ctDNA's role in recurrence prediction in colorectal and lung cancers, suggesting benefits for personalized therapy.

Key Points

  • To review the clinical applications and evidence of molecular residual disease monitoring in solid tumors.
  • Analyzed advances in liquid biopsy technologies, focusing on ctDNA analysis.
  • Compared tumor-informed and tumor-uninformed ctDNA assays.
  • Reviewed landmark trials including DYNAMIC, GALAXY, and TRACERx.
  • Demonstrated ctDNA's prognostic value for recurrence risk in colorectal cancer and NSCLC.
  • Highlighted benefits of ctDNA analysis for guiding adjuvant therapy decisions.
  • Identified ongoing research to standardize MRD assessment in precision oncology.

Cite This Study

Sung Hee Lim (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e389https://doi.org/10.3904/kjm.2025.100.6.274
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Liquid biopsy for minimal residual disease and monitoring in early-stage non-small cell lung cancer: current clinical utility and implementation challenges2025
  2. 2Personalized and Tumor Informed Circulating Tumor DNA Assay for Molecular Residual Disease Monitoring of Solid Malignancies2025 · 3 citations
  3. 3Circulating Tumor DNA-Based Molecular Residual Disease After Curative-Intent Therapy in Non-Small Cell Lung Cancer: An Umbrella Review of Diagnostic Accuracy, Recurrence Prediction, and Adjuvant-Treatment Guidance2026
  4. 4Liquid Biopsy in Gastrointestinal Cancers: Circulating Tumor DNA for Molecular Residual Disease Assessment and Early Treatment Monitoring2026 · 4 citations
  5. 5Circulating-tumour DNA (ctDNA) in NSCLC: mechanisms, evidence and the future of MRD detection2026